A plethora of immunotherapies, including immune checkpoint inhibitors, T-cell therapy, monoclonal antibodies, and immune system modulators, have been developed in the past several decades to treat growing global incidences of cancer. However, these therapies are not without risk. This webinar will highlight innovative immunotherapeutic strategies using genetic engineering approaches that modify a patient's own immune cells to more precisely target cancers, while concurrently minimizing the risk of adverse responses.
Chris DeRenzo, MD, MBA
Department of Bone Marrow Transplantation and Cellular Therapy
St. Jude Children’s Research Hospital
Sandro Matosevic, PhD
Assistant Professor, Industrial and Physical Pharmacy
Interested in sponsoring a webinar?
Click here to contact our friendly sales team.